management-header-3.jpg

Meet our Board of Directors.

Providing expert guidance and strategic insight to help us fulfill our mission to discover, develop and commercialize life changing therapies for children and adults affected by CNS disorders and rare diseases.

Michael R. Dougherty, Director 

Michael R. Dougherty has served on our Board since February 2017. Mr. Dougherty has over 30 years of experience in the biopharmaceutical industry, most recently serving as executive chairman of Celator Pharmaceuticals, Inc. (sold to Jazz Pharmaceuticals). Prior to Celator, Mr. Dougherty was chief executive officer and a member of the board of directors of Kalidex Pharmaceuticals, Inc.  Mr. Dougherty also served in a number of capacities during his ten-year tenure at Adolor Corporation, including president and chief executive officer, member of the board of directors, chief operating officer, and chief financial officer. Prior to Adolor, Mr. Dougherty was president and chief operating officer of Genomics Collaborative, Inc. and served in a variety of senior positions at Genaera Corporation, including president and chief executive officer and member of the board of directors, and at Centocor, Inc. Mr. Dougherty is currently on the board of directors at Trevena, Inc., and previously served as a member of the boards of directors of Foundation Medicine, Inc., Aviragen Therapeutics, Cempra, Inc., and Viropharma Incorporated.  Mr. Dougherty received a bachelor’s degree in accounting from Villanova University.

icon patient resources

Explore Patient Resources

Find helpful information and patient networks, as well as clinical trial opportunities.

View Patient Resources

icon join marinus team

Join the Marinus Team

Learn how you can become part of our mission to advance mindful innovation.

Visit Careers Center